Enovis Corporation · NYSE:ENOV
Enovis — 2025 JP Morgan Healthcare Conference
24 slides from Enovis's conference presentation, Jan 13, 2025
Slide 1: 2025 JP Morgan Healthcare Conference
2025 JP Morgan Healthcare Conference Matt Trerotola Chair, Chief Executive Officer Ben Berry Chief Financial Officer Kyle Rose Vice President, Investor Relations Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans
Slide 3: Two Attractive Ortho Business Segments
Two Attractive Ortho Business Segments Strong Portfolio, Diversified End-Markets, Attractive Growth Drivers Sales Mix by Geography & Segment (1) Fast growing reconstructive (Recon) platform Above market growth engine with attractive portfolio ~50% of business in fast growing extremities (shoulder /
Slide 4: The Fundamentals of Our Strategy
The Fundamentals of Our Strategy Fuel Innovation Partner with healthcare professionals to develop share-shifting solutions that improve outcomes and workflows Operating Excellence Drive continuous Improvement & productivity leveraging our EGX business system Strategic M&A Leverage M&A and integratio
Slide 5: We Have a Rich History of Transformation & Value Creation
We Have a Rich History of Transformation & Value Creation Shaped the Company to a 100% Focused MedTech (Orthopedics) Innovator Diversified Industrial Player established by Danaher Founders Acquired DJO to reshape the business into MedTech Spun out ESAB to become pure play MedTech innovator Enovis 19
Slide 6: Consistent Financial Execution Since Spin
Consistent Financial Execution Since Spin Committed To Delivering on LRP goals of HSD Growth and >50bps Leverage Revenues Adjusted Gross Margins Adjusted EBITDA MARGIN 1Represents full-year 2024 comparable revenue guidance as of 9/27/2024 * Represents LSEG/Refinitiv consensus estimates as of 1/10/25
Slide 7: Shaping Our Company Towards Higher Growth
Shaping Our Company Towards Higher Growth $ $ $ High Growth Categories (HSD/LDD CAGR): Shoulder Foot and Ankle Knee Recovery Sciences / New modalities Moderate Growth Categories (MSD/HSD CAGR): Hip US Bracing / Healthcare Solutions OUS P&R Recovery Sciences / Bone Growth Stimulation Low Growth Categ
Slide 8: Shape P&R to Higher Growth Transformation Through Strategic Acquisitions
Shape P&R to Higher Growth Transformation Through Strategic Acquisitions Accelerating Revenue Growth and Margin Profile with +20 Acquisitions since 2019 2 technology acquisitions- 2020 20241 2023 2022 2021 LiteCure Laser Key M&A Themes: Globalize Recon Advance Enabling Technology Build differentiate
Slide 9: Intentional Global Diversification – Fuels Growth & Margin
Intentional Global Diversification – Fuels Growth & Margin Key Markets Manufacturing International as percentage of Enovis sales: 2019 2024e >40% 27% Shareholder Value Driven By: Established global scale across both P&R and Recon Focused M&A to build direct & indirect channels Expansion via entry in
Slide 10: Uniquely Positioned Across Full Ortho Care Continuum
Uniquely Positioned Across Full Ortho Care Continuum PREVENTION Off-loading braces Back braces Cold therapy SURGICAL Shoulders Knees Hips Foot/Ankle RECOVERY Post-op braces Walker boots Cold therapy PERFORMANCE Athletic braces Muscle stimulation REHAB Electrotherapy Laser therapy Heat/cold therapy T
Slide 11: $1B Reconstructive Innovator with Attractive Portfolio and Mix
$1B Reconstructive Innovator with Attractive Portfolio and Mix Leading in Shoulder, winning across Recon with measurably better patient outcomes AltiVate® EMPOWR® Market Leadership Recon Sales & Market Position1 Technology and Brand Leadership Arvis DynaNail® Ceramics #3 Globally in Shoulder ~5x US
Slide 12: Integration of Lima Continues to Track Above Expectations
Integration of Lima Continues to Track Above Expectations 2024 Goals Progress 3 Year Goals/Focus Exceeded Year 1 Plan, Clear Path to Deliver Against 3 Year Goals Retain Key Talent & Partners Integrate Commercial Channel with less than $30M impact Capture greater than $10M of cost synergies in year 1
Slide 13: Fast-Growing Recon Business with Proven Playbook
Fast-Growing Recon Business with Proven Playbook Sustained strong DD growth across segments US Shoulder US Hip / Knee Foot & Ankle International AltiVate Reverse® & ARG SMR Prima Reverse Arvis® EMPOWR 3D Knee® EMPOWR Revision Knee™ & Cones Arvis® Collared Stem & Impactor (2025) DynaNail® & DynaClip®
Slide 14: Where and How we Continue to Win in Recon
Where and How we Continue to Win in Recon Leading kinematic designs for knee and shoulder implants Next Generation Minimally Invasive Solutions Ceramys Ceramics Dynamic Compression Technology Trabecular Titanium, P2 Proprietary Augmented Reality World class KOLs and Medical Education programs Proven
Slide 15: Enovis Recon Growth Formula
Enovis Recon Growth Formula % of Enovis Recon Market Growth1 Projected Growth vs. Market Growth Projection US Shoulder ~20% 6-7% >1.5x HSD/DD US Hip / Knee ~20% 4-5% >2x HSD/DD Foot / Ankle ~10% 7-8% >1.5x DD Int’l Recon ~50% ~5% ~1.5-2x HSD/DD 5-6% WAMGR 1.5-2X Market Growth HSD/DD Clear track reco
Slide 16: Expanding Enabling Tech Solutions Across Settings & Anatomies
Expanding Enabling Tech Solutions Across Settings & Anatomies Pre-Op Patient Data Patient Selection Pre-Surgical Planning Match Point System® OaraScore® Intra-Op Post-Op Patient Specific Solutions Nav-igation Automation & Execution AR & MR Key Enovis Technologies: Predictive tool to determine outpat
Slide 17: Enabling Tech: Where we’re Investing, What’s coming in 2025
Enabling Tech: Where we’re Investing, What’s coming in 2025 AI Driven Planning & Analytics Ongoing investments in: Key Upcoming Launches: Arvis® Knee 3.0 – Soft Tissue Balancing Arvis® Shoulder 2.0 – Full Glenoid Capability Arvis® International launch Next Generation Advanced Pre-Op Planning Solutio
Slide 18: Market Leader in Prevention & Recovery with Differentiated Brands
Market Leader in Prevention & Recovery with Differentiated Brands P&R Sales & Market Position1 Market Leadership Technology and Brand Leadership $5B market expected to grow ~3% per year Industry-defining products across Orthopedics Sustainable demographic and conservative care demand drivers MotionM
Slide 19: Shaping P&R - Driving Core Growth & Accelerating Key Strategies
Shaping P&R - Driving Core Growth & Accelerating Key Strategies Shaping to MSD growth with Healthy Cash Flow and Consistent Profit Expansion Continue Shaping the Portfolio Drive Operational Excellence & Cash Flow Focus on Healthcare Solutions Growth Digital Solutions for New Growth Vectors Improve v
Slide 20: We Are Shaping Our Future
We Are Shaping Our Future: Enovis is committed to innovation, commercial excellence, consistent operating leverage and delivering shareholder value over long-range plan HSD Organic growth HSD/DD Recon + LSD/MSD P&R +50 bps annual margin expansion +additional from Lima synergies in 2025/2026 70-80% F
Slide 21: Appendix
GH) Appendix a), o. SEX
Slide 22: Gross Margin Bridge
Gross Margin Bridge Enovis Corporation Jn (GAAP) Adj Dollars in millions (Unaudited) December 31,2023, December 31, 2021 Net sales s 17072 14262 Gross profit s 908, ma ‘Gross Margin (GAAP) 580% 545% ‘Gross profit (GAAP) s 08S 94S ma Inventory step-up ors 28 wos Restructuring and other charges 26S 7
Slide 23: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation
Slide 24: Creating Better Together